Trials / Active Not Recruiting
Active Not RecruitingNCT06748053
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Dose Finding, Parallel Group, Phase 2 Study of an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 307 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK5784283 | GSK5784283 will be administered. |
| DRUG | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2025-02-10
- Primary completion
- 2026-07-17
- Completion
- 2027-09-09
- First posted
- 2024-12-24
- Last updated
- 2026-03-23
Locations
138 sites across 9 countries: United States, Bulgaria, Canada, Czechia, Germany, Japan, Romania, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06748053. Inclusion in this directory is not an endorsement.